Efficacy and Safety of Auriclosene (NVC-422) in the Treatment of Bacterial Conjunctivitis

• Status: Completed
• Trial end date: 2015-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the microbiological and clinical efficacy of Auriclosene compared to its vehicle for bacterial conjunctivitis. Adults and children one year of age and older with bacterial conjunctivitis in at least one eye may be eligible. Subjects will be randomly assigned to receive either Auriclosene Ophthalmic Solution or Vehicle Ophthalmic Solution.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: NovaBay Pharmaceuticals, Inc.
• Treatments: Ophthalmic Solutions; Pharmaceutical Solutions

Criteria

Inclusion Criteria:

• 1 year of age and older

• Bulbar conjunctival injection

• Conjunctival discharge/exudate

• Signs and symptoms of bacterial conjunctivitis in at least one eye for 3 days or less

• Other inclusion criteria per protocol

Exclusion Criteria:

• Suspected fungal, viral, Chlamydia or Acanthamoeba co-infection based on clinical diagnosis

• Any drug treatment in either eye for the current episode of bacterial conjunctivitis prior to study enrollment

• Other exclusion criteria per protocol